Oral vaccination with an adenovirus-vectored vaccine protects against botulism

Vaccine

Volumn 31, Issue 7, 2013, Pages 1009-1011

  Chen, Shan ^a   Xu, Qingfu ^b   Zeng, Mingtao ^a  

^a Texas Tech University Health Sciences Center El Paso   (United States)

^b ROCHESTER GENERAL HOSPITAL   (United States)

Author keywords

Botulinum neurotoxin; Oral vaccination; Protective immunity; Recombinant adenovirus; Toxin neutralization

Indexed keywords

ADENOVIRUS VACCINE; ADENOVIRUS VECTOR; BACTERIAL VACCINE; BACTERIUM ANTIBODY; BOTULINUM TOXIN; BOTULINUM TOXIN C; BOTULINUM VACCINE; IMMUNOGLOBULIN HEAVY CHAIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL IMMUNITY; BLOOD SAMPLING; BOTULISM; CONTROLLED STUDY; FEMALE; HUMAN ADENOVIRUS 5; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS RECOMBINANT;

ADENOVIRUSES, HUMAN; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTITOXINS; BACTERIAL VACCINES; BOTULINUM TOXINS; BOTULISM; DRUG CARRIERS; FEMALE; GENETIC VECTORS; MICE; MICE, INBRED BALB C; SURVIVAL ANALYSIS; VACCINATION; VACCINES, SYNTHETIC;

EID: 84872605436     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.054     Document Type: Article

References (18)

1. Rusnak J.M., Smith L.A. Botulinum neurotoxin vaccines: past history and recent developments. Hum Vaccin 2009, 5(December (12)):794-805.
2. Botulism in the United States, 1899-1998. Handbook for epidemiologists, clinicians and laboratory workers 1998, Centers for Disease Control and Prevention, Atlanta, GA. U.S. Department of Health and Human Services PHS (Ed.).
3. CDC Notice of CDC's discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. Morb Mortal Wkly Rep (MMWR) 2011, 60(October (42)):1454-1455.
4. Xu Q., Pichichero M.E., Simpson L.L., Elias M., Smith L.A., Zeng M. An adenoviral vector-based mucosal vaccine is effective in protection against botulism. Gene Ther 2009, 16(March (3)):367-375.
5. Zeng M., Xu Q., Elias M., Pichichero M.E., Simpson L.L., Smith L.A. Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine 2007, 25(October (43)):7540-7548.
6. Kimura K., Fujii N., Tsuzuki K., Murakami T., Indoh T., Yokosawa N., et al. The complete nucleotide sequence of the gene coding for botulinum type C1 toxin in the C-ST phage genome. Biochem Biophys Res Commun 1990, 171(September (3)):1304-1311.
7. Nowakowski A., Wang C., Powers D.B., Amersdorfer P., Smith T.J., Montgomery V.A., et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A 2002, 99(August (17)):11346-11350.
8. Byrne M.P., Smith T.J., Montgomery V.A., Smith L.A. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun 1998, 66(October (10)):4817-4822.
9. White D.M., Pellett S., Jensen M.A., Tepp W.H., Johnson E.A., Arnason B.G. Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells. Infect Immun 2011, 79(August (8)):3388-3396.
10. Zichel R., Mimran A., Keren A., Barnea A., Steinberger-Levy I., Marcus D., et al. Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system. Clin Vaccine Immunol 2010, 17(May (5)):784-792.
11. Yu Y.Z., Zhang S.M., Sun Z.W., Wang S., Yu W.Y. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A. Vaccine 2007, 25(December (52)):8843-8850.
12. Yu Y.Z., Li N., Zhu H.Q., Wang R.L., Du Y., Wang S., et al. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine 2009, 27(May (21)):2816-2822.
13. Colloca S., Barnes E., Folgori A., Ammendola V., Capone S., Cirillo A., et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012, 4(January (115)):115ra2.
14. Croyle M.A., Patel A., Tran K.N., Gray M., Zhang Y., Strong J.E., et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS ONE 2008, 3(10):e3548.
15. Zeng M., Xu Q., Hesek E.D., Pichichero M.E. N-fragment of edema factor as a candidate antigen for immunization against anthrax. Vaccine 2006, 24(January (5)):662-670.
16. Lin S.W., Cun A.S., Harris-McCoy K., Ertl H.C. Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut. Vaccine 2007, 25(March (12)):2187-2193.
17. Li J., Faber M., Papaneri A., Faber M.L., McGettigan J.P., Schnell M.J., et al. A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice. Virology 2006, 356(December (1-2)):147-154.
18. Xiang Z.Q., Gao G.P., Reyes-Sandoval A., Li Y., Wilson J.M., Ertl H.C. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 2003, 77(October (20)):10780-10789.